ASSAY and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.
ASSAY and Drug Development Technologies coverage includes:
- Assay design, target development, high-throughput technologies, and chemistry
- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis
- Approaches to assays configured for gene families, inherited, and infectious diseases
- Assays and strategies for adapting model organisms to drug discovery
- The use of stem cells as models of disease
- Translation of phenotypic outputs to target identification
- Exploration and mechanistic studies of the technical basis for assay and screening artifacts
ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Andrew D. Napper, PhD, Nemours/A.I. duPont Hospital for Children; and other leading investigators. View the entire editorial board.
New in Fall 2015
Beginning in Fall 2015 ASSAY and Drug Development Technologies will be featuring a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section in the journal. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.
This DRRR special section will feature original papers, application-oriented technology reviews, and reports in methodology and technology application to drug repurposing and redevelopment including:
- Designing assays and interpreting output to enable alternate drug target identification
- Pathway analysis and bioinformatics to identify and exploit drug promiscuity
- In silico technologies to identify alternate drug targets
- "Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U.
Journal Audience Includes: Drug discovery and developmental scientists, pharmaceutical and biotechnology researchers, and disease foundation specialists, among others.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.